VA
MIRM icon

Vident Advisory’s Mirum Pharmaceuticals MIRM Stock Holding History

Vident Advisory’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$609K Buy
5,198
+565
+12% +$56.7K ﹤0.01% 1258
2026
Q1 		$428K Buy
+4,633
New +$436K ﹤0.01% 1340

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vident Advisory's MIRM Position: Q2 2026 in Review

Vident Advisory increased its Mirum Pharmaceuticals (MIRM) stake by 12% in Q2 2026, buying an estimated $56.7K and bringing the position to 5,198 shares worth $609K. The position accounts for ﹤0.01% of the portfolio, ranked #1258.

Vident Advisory first reported a position in MIRM in Q1 2026 and has held it in 2 quarters since. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • Vident Advisory held 5,198 shares of Mirum Pharmaceuticals worth $609K as of Q2 2026.
  • Vident Advisory bought 565 Mirum Pharmaceuticals shares in Q2 2026, an estimated $56.7K.
  • Mirum Pharmaceuticals made up ﹤0.01% of Vident Advisory's portfolio in Q2 2026, its #1258 holding.
  • Vident Advisory first reported a position in Mirum Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.